Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Recruiting
NCT07216703Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Cervical Cancer
United States, Argentina, Austria, Belgium, Brazil +22 more
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Recruiting
NCT07419295Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer
United States, Argentina, Australia, Belgium, Brazil +11 more
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaRecruiting
NCT07219173Phase 2Updated Jul 27, 2026
Sponsor: Eli Lilly and Company
Asthma
United States, Argentina, Brazil, Canada, China +7 more
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruiting
NCT06158841Phase 3Updated Jul 27, 2026
Sponsor: AbbVie
Multiple Myeloma
United States, Australia, Austria, Belgium, Canada +20 more
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerRecruiting
NCT07525206Phase 3Updated Jul 27, 2026
Sponsor: AbbVie
Colorectal Cancer
United States, Belgium, Japan, Portugal, South Korea +2 more
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)Recruiting
NCT07227311Phase 2Updated Jul 24, 2026
Sponsor: GlaxoSmithKline
Multiple Myeloma
United States, France, Germany, Greece, Japan +3 more
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)Recruiting
NCT07366034Phase 3Updated Jul 24, 2026
Sponsor: Boehringer Ingelheim
Fibrosing Interstitial Lung Disease
United States, Argentina, Australia, Belgium, Brazil +17 more
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruiting
NCT07354074Phase 2Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
United States, Australia, Canada, China, France +6 more
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyRecruiting
NCT05889182Phase 3Updated Jul 24, 2026
Sponsor: AbbVie
Hidradenitis Suppurativa
United States, Argentina, Australia, Austria, Belgium +32 more
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Recruiting
NCT06568939Phase 2Updated Jul 24, 2026
Sponsor: AbbVie
Non-Small Cell Lung Cancer
United States, Brazil, China, Israel, Japan +2 more
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruiting
NCT07492641Phase 3Updated Jul 24, 2026
Sponsor: BeOne Medicines
HR+/HER2- Breast Cancer
United States, Australia, China, Japan, Malaysia +2 more
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)Recruiting
NCT06929273Phase 3Updated Jul 24, 2026
Sponsor: Bristol-Myers Squibb
Bipolar Disorder Type I With Mania
United States, Argentina, Australia, Bulgaria, China +15 more
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive Not Recruiting
NCT05648968Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
United States, Argentina, Australia, China, France +11 more
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCRecruiting
NCT06855277Phase 3Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Prostate Cancer
United States, Australia, Brazil, China, Hong Kong +6 more
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate CancerActive Not Recruiting
NCT03456843Phase 2Updated Jul 24, 2026
Sponsor: Yale University
Stage IV Prostate Adenocarcinoma AJCC v7
United States, Australia, China, Japan, South Korea +1 more
First-Time-in-Human Study of GSK5471713 in Adults With mCRPCRecruiting
NCT07332455Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: GlaxoSmithKline
Neoplasms, Prostate
United States, Australia, Canada, Japan, South Korea
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityRecruiting
NCT07037433Phase 3Updated Jul 24, 2026
Sponsor: Amgen
Atherosclerotic Cardiovascular Disease · Overweight · Obesity
United States, Argentina, Australia, Austria, Belgium +31 more
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine CancersNot Yet Recruiting
NCT07707895Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Boehringer Ingelheim
Small Cell Lung Cancer · Large Cell Neuroendocrine Lung Carcinoma · Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology · Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
United States, Australia, Belgium, China, France +6 more
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruiting
NCT07195695Phase 3Updated Jul 24, 2026
Sponsor: Boehringer Ingelheim
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Recruiting
NCT03486873Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Solid Tumors · Hematologic Malignancies
United States, Argentina, Australia, Austria, Belgium +46 more
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusEnrolling By Invitation
NCT04976322Phase 3Updated Jul 24, 2026
Sponsor: UCB Biopharma SRL
Systemic Lupus Erythematosus
United States, Argentina, Belgium, Bulgaria, Canada +19 more
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.Completed
NCT05523167Phase 2, Phase 3Updated Jul 24, 2026
Sponsor: argenx
Active Idiopathic Inflammatory Myopathy · Myositis · Dermatomyositis · Polymyositis
United States, Argentina, Australia, Austria, Belgium +31 more
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerRecruiting
NCT07392892Phase 2, Phase 3Updated Jul 24, 2026
Sponsor: Pfizer
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma · Metastatic Gastric Cancer · Gastroesophageal Junction Cancer · Esophageal Adenocarcinoma
United States, China, Israel, Japan, Puerto Rico +1 more
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)Recruiting
NCT07340827Phase 3Updated Jul 24, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Infertility
Japan
Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) PollinosisRecruiting
NCT07726147Phase 1Updated Jul 24, 2026
Sponsor: Immunomic Therapeutics, Inc.
Allergen Immunotherapy
Japan

Previous page Next page